575 MADISON AVENUE, NEW YORK, NY
Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
Appoints Joseph Miller as Chief Financial Officer
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Ex-99.1
Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
Chief Medical Officer Resignation - Anna Eramo Steps Down
2026 Annual Meeting Results - Directors Elected at LB Pharmaceuticals
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Q2
Q1
Q3
Effectiveness Notice
S-3ASR
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
S-1MEF